Bibliography
- Vazquez E, Sanchez-Perales C, Borrego F, Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000;140:886-90
- Genovesi S, Pogliani D, Faini A, Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005;46:897-902
- Winkelmayer WC, Patrick AR, Liu J, The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 2011;22:349-57
- Sanchez-Perales C, Vazquez E, Garcia-Cortes MJ, Ischaemic stroke in incident dialysis patients. Nephrol Dial Transplant 2010;25:3343-8
- Seliger SL, Gillen DL, Longstreth WT, Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003;64:603-9
- Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004;30:579-89
- US Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2011
- Chan KE, Lazarus M, Thadhani R, Warfarin Use Associates with increased risk For stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-33
- Wizemann V, Tong L, Statayathum S, Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77:1098-106
- Olesen JB, Lip GYH, Kamper AL, Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625-35
- Lip GY. Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of thromboembolism and bleeding risk. Europace 2011;13:145-8
- Salam A, Salim I, Al Suwaidi J, Ghadban W. Anticoagulation in atrial fibrillation and coexistent chronic kidney disease; efficacy versus safety. Expert Opin Drug Saf 2013;12(1):53-63
- Eikelboom JW, Wallentin L, Connolly S, Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial. Circulation 2011;123:2363-72
- Fox KAA, Piccini JP, Wojdyla D, Prevention of stroke and sistemi embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32(19):2387-94
- Stangier J, Ratugen K, Stahle H, Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. An Open-Label, Parallel-Group, Single-Centre Study. Clin Pharmacokinet 2010;49:259-68
- Hohnsloer SH, Oldgren J, Yang S, Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-term anticoagulation therapy) trial. Circulation 2012;125:669-76